Clinuvel Pharmaceuticals Files Marketing Authorisation Dossier for NEURACTHEL® Instant in Europe
Clinuvel Pharmaceuticals has submitted a marketing authorisation dossier for its second pharmaceutical product, NEURACTHEL® Instant (tetracosactide), to European regulators via the decentralised procedure.